Bevirimat is primarily investigated for its potential as an antiviral agent, particularly in the treatment of HIV-1 infection. It functions by inhibiting the maturation process of the HIV-1 virus, specifically targeting the cleavage of the Gag protein, which is essential for the production of mature and infectious viral particles. This mechanism makes it a promising candidate for use in combination antiretroviral therapy (ART), potentially offering a new approach to managing HIV in patients who have developed resistance to other drugs. Research is ongoing to evaluate its efficacy, safety, and potential role in improving treatment outcomes for individuals living with HIV.